ArticleUrologia internationalis2026
Parameters Predicting Recurrence after Focal Therapy for Prostate Cancer: Insights from a Multicenter Surveillance Database.
Article in Urologia internationalis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFocal therapy (FT) represents a minimally invasive option for selected patients with localized prostate cancer (PCa), aiming to achieve oncological control while preserving functional outcomes. Despite its increasing adoption, long-term efficacy data remain limited and predictors of recurrence are not well defined.
methodsWe conducted a retrospective multicenter cohort study of 209 men with histologically confirmed unifocal or oligo-focal (≤3 lesions) PCa treated with FT (high-intensity focused ultrasound [HIFU], vascular-targeted photodynamic therapy [VTP], cryotherapy, or transurethral ultrasound ablation [TULSA]) between 2019 and 2024 at three German centers. Clinical, histopathological, treatment-related, and multiparametric magnetic resonance imaging (mpMRI) parameters were prospectively collected in a REDCap-based registry. Recurrence-free survival (RFS) and progression-free survival (PFS) were analyzed using Kaplan-Meier estimates, and Cox regression was applied to identify independent predictors.
resultsMedian patient age was 66 years and median prostate-specific antigen was 6.4 ng/mL. ISUP grade distribution was 58% grade 1, 29% grade 2, and 13% grade ≥3. Treatment modalities comprised HIFU (43%), VTP (35%), cryotherapy (12%), and TULSA (10%). After a median follow-up of 1.73 years, 40% of patients developed recurrence and 15% showed histologic progression. RFS varied by treatment modality (HIFU: 2.26 years; VTP: 1.73 years; cryotherapy: 0.75 years; TULSA: not reached; p = 0.001). Median PFS was 4.7 years. Suspicious baseline mpMRI (PI-RADS 4-5) was associated with shorter RFS. Suspicious follow-up mpMRI strongly predicted both recurrence (RFS 1.1 vs. 2.96 years, p < 0.001) and progression (PFS 1.8 vs. 4.7 years, p = 0.004). In multivariate analysis, suspicious follow-up mpMRI was the only independent predictor of recurrence (HR: 2.07, 95% CI: 1.24-3.45, p = 0.005).
conclusionsIn this multicenter registry analysis, recurrence after FT was frequent, affecting 40% of patients within 2 years. mpMRI findings before and especially after treatment emerged as the strongest predictors of oncological failure, underscoring the central role of standardized imaging in patient selection and surveillance. Prospective studies with longer follow-up and centralized radiologic review are needed to refine FT protocols and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.